""We want everything to move really, really fast and we want to get a new molecule that's going to change the world in another six months," says Diogo Rau, Eli Lilly's chief information and digital officer. But despite that urgency, Rau acknowledges that science still takes time. New drug discovery can take well over a decade and well north of $2 billion, on average, before they can obtain regulatory approval."
"Separately, J&J on the same day, announced its own partnership with Nvidia, relying on the AI company's foundation models to create simulated environments for surgical teams to plan their kidney stone procedures. J&J says this application of so-called "physical AI" will optimize the process to map out procedures, make it easier to train doctors, and will result in more consistent and better clinical outcomes for patients."
Nvidia has entered partnerships with Eli Lilly and Johnson & Johnson to apply advanced chips and AI models to pharmaceutical research and surgical planning. Eli Lilly plans a Nvidia-chip powered supercomputer and AI factory by early 2026 to run models trained on millions of experiments and will share some proprietary models via Lilly TuneLab for smaller biotech access. J&J will use Nvidia foundation models to build simulated, 'physical AI' environments that let surgical teams rehearse kidney stone procedures, standardize planning, and improve training. Company leaders emphasize urgency to accelerate discovery while acknowledging that drug development remains time-consuming and costly.
Read at Fortune
Unable to calculate read time
Collection
[
|
...
]